Company intelligence / Profile preview

NeoPrediX

Basel, Basel, Switzerlandx.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeoPrediX has developed a proprietary digital health platform that uses advanced algorithms to predict risks of various maternal, neonatal, and perinatal conditions. Their solutions are designed to help clinicians identify at-risk newborns early—potentially reducing morbidity and mortality. The company’s first product has demonstrated high accuracy (>90%) in trials and was commercially launched in the US with initial hospital customers signed up. European rollout follows soon after.

Therapeutic areas: OtherImmunologyWomen's Health
Modalities: Non-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

Hospitals/health systems in the US and EuropeSpringhood Ventures as strategic investor focused on children’s health innovation

Beyond the preview

Go deeper on NeoPrediX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoPrediX.

Explore the full profile